Overview
SCNX market data
Price History
SCNX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.70 Diluted earnings per share over the trailing twelve months.
- Beta
- 3.01 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 1,428.6% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.24 – $2.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $15.3 · P/B 0.30 · P/S 23.69.
Company News
Scienture To Begin Shiptments Of REZENOPY Nasal Spray 10mg To U.S. Pharmaceutical Wholesalers Later This MonthBenzinga · Jul 9, 2026, 12:20 PM
Scienture Announces Progress Towards Commercialization Of Its Arbli Oral Suspension Including Expanded Payor Coverage, Broader Pharmacy Access And New Channel PartnershipsBenzinga · Jun 18, 2026, 12:15 PM
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid OverdoseBenzinga · Jun 16, 2026, 12:55 PM
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial LaunchBenzinga · Jun 9, 2026, 11:50 AM
EXCLUSIVE: SCIENTURE Secures Formulary Coverage For REZENOPY; Commercial Launch Planned For Mid-JulyBenzinga · Jun 9, 2026, 11:50 AM
Scienture Holdings Holds Exclusive U.S. Distribution Rights For Kindeva Drug Subsidiary Summit BioSciences' Rezenopy Nasal Spray, Which Received A U.S. Patent Effective May 12Benzinga · Jun 2, 2026, 12:23 PM
Scienture Eric Sherb Resigns As CFO Effective May 26, 2026; Narasimhan Mani Appointed As Interim CFO Effective May 26, 2026Benzinga · May 29, 2026, 9:10 PM
8-K filing — Scienture Holdings, Inc. (SCNX)SEC EDGAR · May 29, 2026, 9:00 PM
Scienture Holdings Q1 EPS $(0.08) Beats $(0.22) Estimate, Sales $56.325K Up From $10.258K YoYBenzinga · May 15, 2026, 10:12 PM